- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06267430
Learning by Heart: The Effectiveness of an EF Training Program for Pre-schoolers With a Severe CHD (LbH)
The Effectiveness of a Personalized Executive Functioning Training Program for Pre-schoolers With a Severe Congenital Heart Disease
Study Overview
Status
Intervention / Treatment
Detailed Description
Advances in prenatal and neonatal care have improved outcome in children with severe congenital heart disease (CHD), with survival rates up to 90%. With the increase in survival, neurocognitive problems and psychological maladjustment have become more apparent in these children, such as impairments in their executive functioning. Executive functioning (EF) is an umbrella-term for several higher-order cognitive processes crucial for self-regulated and goal directed behaviour. Frequently postulated components of EF are inhibition, including motor inhibition, and attention, working memory, and cognitive flexibility. Early EF problems often result in emotion regulation difficulties, behavioural problems, social problems, and learning problems, which can lead to diminished functioning in social domains and lower achievement levels in education and employment status. Children with CHD might be rendered even more vulnerable for EF-problems since EF development is embedded within the social context of a child. There is an increasing understanding of how naturally distressing the CHD diagnosis and treatment can be for parents, which can impair the interactions with their child and in turn might negatively impact the child's EF development. Looking at the reciprocal nature of relationships, the child's illness and/or emotional and behavioural problems that may be associated with EF difficulties might negatively impact the parent-child relationship, parenting behaviour and parental wellbeing. However, these relations are poorly understood, especially regarding fathers. A greater understanding of the interplay between biological and psychosocial factors on EF-development is needed to promote optimal developmental outcomes for these vulnerable children.
New insights suggest that EF can be improved by training. Due to neural plasticity, the window for effective training seems to be between the ages of two and six years. After this time frame, improvements in EF may not retain after training or not generalize to off-task functions. Current EF training programs are not personalised ('adaptive') but offer the same program regardless of the specific child's EF dysfunctions, which may explain their limited effects. There is presently no effective EF training program for children with CHD.
In a pilot study funded by Stichting Hartekind, the researchers investigated the feasibility of a personalised EF training program called 'KleuterExtra' in 4-6 year old children with severe CHD. Within a week, 31 children were (self-) referred for the study, indicating a great clinical need. Directly after training, children showed clinically relevant improvement on the specific EFs targeted in training, with Cohen's d effect sizes ranging from 0.19 to 2.41 (>1.00 on 5 out of 9 tasks). Improvement was also found in untrained EFs and tasks that combined multiple EFs, indicating a generalization effect. Parents and teachers spontaneously reported positive results in daily life. Based on these promising results, the investigators designed the current randomized, controlled study to test the effectiveness of this training program in pre-schoolers with severe CHD.
Given the above, the investigators designed this study to investigate the effectiveness of a tailored EF training program for preschoolers with severe CHD. Secondary aim was to explore interactions between the parent-child relationship and the EF development of the child. If found effective, EF training for children with severe CHD will improve their developmental outcome.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Eveline Oppelaar
- Phone Number: 0031107040209 0031107040209
- Email: e.oppelaar@erasmusmc.nl
Study Contact Backup
- Name: André Rietman
- Phone Number: 0031107040209 0031107036090
- Email: a.rietman@erasmusmc.nl
Study Locations
-
-
-
Groningen, Netherlands, 9713GZ
- Recruiting
- University Medical Center - Beatrix children's hospital Groningen
-
Contact:
- Hessel Nijenhuis
- Email: h.p.nijenhuis@umcg.nl
-
Rotterdam, Netherlands, 3015CN
- Recruiting
- Erasmus Medical Center Sophia Children's Hospital
-
Contact:
- André Rietman
- Email: a.rietman@erasmusmc.nl
-
Utrecht, Netherlands, 3584EA
- Not yet recruiting
- University Medical Center - Wilhelmina children's hospital Utrecht
-
Contact:
- Hans Breur
- Phone Number: +31 88 75 754 59
- Email: h.breur@umcutrecht.nl
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Description
In order to be eligible to participate in this study, a child must meet all of the following criteria:
- Aged 4.0 - 6.0 years upon inclusion OR aged 6.0-7.0 years who are still in kindergarten (group 1 & 2 of the Dutch school system)
- Required CHD surgery in the first six months of life (with or without ECMO) or a cyanotic CHD that required surgery in the first 12 months of life
- IQ estimated > 55 (no moderate to severe intellectual disability)
- Diminished EF based on a below average score on any of the subtests of the 'KleuterExtra' test battery (≤ 25 percentile) at t = 0
- Sufficient comprehension of the Dutch language by the child to be able to participate in the EF test battery and the EF training program. In order to be eligible to participate in this study, the parent(s) must meet the following criteria:
- Sufficient comprehension of the Dutch language to understand the study information and to be able to fill out the Dutch questionnaires.
Exclusion Criteria:
- Children receiving targeted EF support at school upon inclusion.
- Children with severe brain damage (estimated IQ < 55)
- Genetic syndromes known to directly affect cognitive performance (e.g. Down syndrome)
- Children with severe psychiatric disorders upon inclusion that require treatment first, such as a posttraumatic stress disorder, separation anxiety disorder, or reactive attachment disorder.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Intervention group
The participants allocated to the intervention group will receive the personalised training program 'KleuterExtra', developed by dr.
Lex Wijnroks from Utrecht University.
All parents will receive the book 'Speels Brein' ('Playful Brain') and an age-appropriate addition for preschoolers to this book.
|
The intervention was described in the included arm/group explanation.
|
|
No Intervention: Control group
As described, the parents of the control group will also receive the book 'Speels Brein' ('Playful Brain') and the age-appropriate addition for preschoolers to this book.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Kleuter Extra test battery
Time Frame: 9 weeks after baseline. Additional measures at 6 months and 12 months after baseline.
|
The primary endpoint is a single composite score on the 'Kleuter Extra' EF test battery.
This composite score will be statistically derived from the individual test results of the test battery.
Therefore, the minimum and maximum values cannot be provided at this point, nor whether a higher score means a better or worse outcome.
|
9 weeks after baseline. Additional measures at 6 months and 12 months after baseline.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
EF functioning
Time Frame: 9 weeks after baseline. Additional measures at 6 months and 12 months after baseline.
|
Single test scores from the ''Kleuter Extra'' EF test battery:
A higher score indicates a better outcome for all subtests, except the 'Pencil Tap' task. The scores are converted into percentiles ranging from the lowest percentile rank (0-3) to the highest percentile rank (>75) with a higher score indicating a better outcome. |
9 weeks after baseline. Additional measures at 6 months and 12 months after baseline.
|
|
Information processing
Time Frame: 9 weeks after baseline. Additional measures at 6 months and 12 months after baseline.
|
Cognitive Proficiency Index of the WPPSI-IV-NL. This index score is based on the test results of the following subtests:
|
9 weeks after baseline. Additional measures at 6 months and 12 months after baseline.
|
|
Executive functioning in daily life - completed by the parent(s)
Time Frame: 9 weeks after baseline. Additional measures at 6 months and 12 months after baseline.
|
Behavior Rating Inventory of Executive Function - Preschool Version questionnaire (BRIEF-P): t-scores range from 20-80, higher scores indicate worse outcome)
|
9 weeks after baseline. Additional measures at 6 months and 12 months after baseline.
|
|
Behavioral and emotional difficulties of the child - completed by the parent(s)
Time Frame: 9 weeks after baseline. Additional measures at 6 months and 12 months after baseline.
|
Child Behavioral Checklist questionnaire 1,5 - 5 years old (CBCL): t-scores range from 50-100, higher scores indicate worse outcome)
|
9 weeks after baseline. Additional measures at 6 months and 12 months after baseline.
|
|
Quality of the child's life - completed by the parent(s)
Time Frame: 9 weeks after baseline. Additional measures at 6 months and 12 months after baseline.
|
Preschool Children Quality of Life questionnaire (TAPQOL): t-scores range from 0 - 100, higher score indicates better outcome.
|
9 weeks after baseline. Additional measures at 6 months and 12 months after baseline.
|
|
Emotional distress parent - completed by the parent(s)
Time Frame: 9 weeks after baseline. Additional measures at 6 months and 12 months after baseline.
|
Depression, Anxiety, Stress Scale (DASS-21): scores range from 0-63, higher score indicates worse outcome)
|
9 weeks after baseline. Additional measures at 6 months and 12 months after baseline.
|
|
Parental trauma
Time Frame: 9 weeks after baseline. Additional measures at 6 months and 12 months after baseline.
|
PCL-5 questionnaire ('PCL-5' is the title, scores range from 0-80, higher score indicates worse outcome)
|
9 weeks after baseline. Additional measures at 6 months and 12 months after baseline.
|
|
Parenting behavior and quality parent-child relationship - completed by the parent(s)
Time Frame: 9 weeks after baseline. Additional measures at 6 months and 12 months after baseline.
|
Parenting Behavior questionnaire (PABI): scores range from 0-525, a higher score can mean a better or worse outcome depending on the specific scale.
|
9 weeks after baseline. Additional measures at 6 months and 12 months after baseline.
|
|
Child demographics teacher's perspective
Time Frame: 9 weeks after baseline. Additional measures at 6 months and 12 months after baseline.
|
Additional support in school, type, being held back a year (qualitative data, designed by the study group)
|
9 weeks after baseline. Additional measures at 6 months and 12 months after baseline.
|
|
Behavioral and emotional difficulties teacher's perspective
Time Frame: 9 weeks after baseline. Additional measures at 6 months and 12 months after baseline.
|
Teacher's Report Form questionnaire (TRF): t-scores range from 50-100, higher scores indicate worse outcome)
|
9 weeks after baseline. Additional measures at 6 months and 12 months after baseline.
|
|
Executive functioning child in daily life teacher's perspective
Time Frame: 9 weeks after baseline. Additional measures at 6 months and 12 months after baseline.
|
Behavior Rating Inventory of Executive Function questionnaire - teachers (BRIEF); t-scores range from 20-80, higher scores indicate worse outcome)
|
9 weeks after baseline. Additional measures at 6 months and 12 months after baseline.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: André Rietman, Erasmus Medical Center
- Principal Investigator: Renske Schappin, Erasmus Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NL85141.078.23
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Congenital Heart Disease
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaRecruitingAdult Congenital Heart Disease | Congenital Heart Disease (CHD) | Pediatric Congenital Heart Disease | Heart Transplant PatientsItaly
-
Seoul National University HospitalUniversity of SeoulNot yet recruitingCongenital Heart Disease in Children | Congenital Heart Disease (CHD) | Complex Congenital Heart DiseaseKorea, Republic of
-
University of UlsterBelfast Health and Social Care TrustCompletedCongenital Heart Disease | Congenital Heart Defect | Adult Congenital Heart DiseaseUnited Kingdom
-
The Children's Hospital of Zhejiang University...Beijing Children's Hospital; Children's Hospital of Nanjing Medical UniversityNot yet recruitingCongenital Heart Disease in Children | Congenital Heart Disease (CHD)China
-
China National Center for Cardiovascular DiseasesPeking University; Shandong University; Guangxi Medical University; Wenzhou Medical... and other collaboratorsActive, not recruitingStructural Heart Disease | Congenital Heart Disease (CHD)China
-
Children's Hospital Medical Center, CincinnatiNational Heart, Lung, and Blood Institute (NHLBI)CompletedHeart Disease CongenitalUnited States
-
Martin SchweigerUniversity Children's Hospital, ZurichRecruitingFontan Physiology | Congenital Heart Disease in Children | Congenital Heart SurgerySwitzerland
-
University Hospital, BordeauxNot yet recruitingCHD - Congenital Heart DiseaseFrance
-
Fondazione Policlinico Universitario Agostino Gemelli...RecruitingAdult Congenital Heart DiseaseItaly
-
University of CalgaryThe Hospital for Sick Children; Alberta Children's HospitalNot yet recruitingCongenital Heart Disease (CHD)
Clinical Trials on Kleuter Extra training program
-
Cairo UniversityNot yet recruitingChronic Ankle Instability, CAIEgypt
-
Universitaire Ziekenhuizen KU LeuvenCompleted
-
Virginia Commonwealth UniversityTerminated
-
Centre Hospitalier Universitaire de NiceTerminated
-
Education University of Hong KongNot yet recruiting
-
Universidad Pablo de OlavideUniversity of SevilleCompletedObesity | Overweight and Obesity | Overweight or ObesitySpain
-
Cairo UniversityCompletedLow Back PainEgypt
-
Marmara UniversityCompletedHealth Individuals | AtlhetesTurkey
-
Riphah International UniversityCompletedDrug Use and AddictionPakistan
-
University GhentSpecial Research Fund, BelgiumCompletedChronical Rotator Cuff TendinopathyBelgium